ursolic acid has been researched along with gemcitabine in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Chun, KH; Kim, J; Kim, Y; Lim, JW; Yoon, Y | 1 |
Li, J; Liang, X; Yang, X | 1 |
Aggarwal, BB; Gupta, SC; Prasad, S; Sung, B; Tyagi, AK; Yadav, VR | 1 |
Chen, SY; Li, ZY; Weng, MH; Yen, GC | 1 |
4 other study(ies) available for ursolic acid and gemcitabine
Article | Year |
---|---|
Discovery of ursolic acid prodrug (NX-201): Pharmacokinetics and in vivo antitumor effects in PANC-1 pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Humans; Mice, SCID; Pancreas; Pancreatic Neoplasms; Prodrugs; Triterpenes; Ursolic Acid; Xenograft Model Antitumor Assays | 2016 |
Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Nude; NF-kappa B; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Random Allocation; Signal Transduction; Triterpenes; Ursolic Acid; Xenograft Model Antitumor Assays | 2012 |
Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Inflammation; Mice; Mice, Nude; Pancreatic Neoplasms; Triterpenes; Tumor Microenvironment; Ursolic Acid; Xenograft Model Antitumor Assays | 2016 |
Ursolic acid restores sensitivity to gemcitabine through the RAGE/NF-κB/MDR1 axis in pancreatic cancer cells and in a mouse xenograft model.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Heterografts; Humans; Mice; NF-kappa B; Pancreatic Neoplasms; Receptor for Advanced Glycation End Products; Triterpenes; Ursolic Acid | 2021 |